Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes.
暂无分享,去创建一个
M. Lübbert | P. Valent | M. Pfeilstöcker | W. Sperr | U. Germing | R. Stauder | T. Nösslinger | O. Krieger | D. Haase | H. Tüchler | A. Giagounidis
[1] M. Gordon. Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion , 2008 .
[2] M. Cazzola,et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] T. Haferlach,et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. , 2007, Leukemia research.
[4] U. Germing,et al. Myelodysplastic syndromes in patients younger than age 50. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] M. Grever,et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. , 2006, Cancer research.
[6] M. Gordon. Efficacy of Lenalidomide in Myelodysplastic Syndromes , 2006 .
[7] C. Steidl,et al. Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS) , 2005, Leukemia.
[8] M. Cazzola,et al. A WHO Classification-Based Prognostic Scoring System (WPSS) for Predicting Survival in Myelodysplastic Syndromes. , 2005 .
[9] Luca Malcovati,et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] P. C. Huang,et al. Genetic and biochemical studies with ataxia telangiectasia , 1981, Human Genetics.
[11] C. Schoch,et al. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31 , 2004, Leukemia.
[12] J. Holland,et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] M. Lübbert,et al. Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] M. Schemper,et al. Predictive Accuracy and Explained Variation in Cox Regression , 2000, Biometrics.
[15] G Flandrin,et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] G Flandrin,et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] M. Pfeilstöcker,et al. Cross‐validation of prognostic scores in myelodysplastic syndromes on 386 patients from a single institution confirms importance of cytogenetics , 1999, British journal of haematology.
[18] T Hamblin,et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.
[19] W. Hiddemann,et al. Evidence for malignant transformation in acute myeloid leukemia at the level of early hematopoietic stem cells by cytogenetic analysis of CD34+ subpopulations , 1995 .
[20] A. Duhamel,et al. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. , 1993, Leukemia.
[21] A. Tefferi,et al. The 5q- syndrome: a single-institution study of 43 consecutive patients. , 1993, Blood.
[22] U. Germing,et al. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. , 1992, Leukemia.
[23] M. Sanz,et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. , 1989, Blood.
[24] H. Gralnick,et al. Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.
[25] D. Schweizer. Counterstain-enhanced chromosome banding. , 1981, Human genetics.
[26] Iscn. International System for Human Cytogenetic Nomenclature , 1978 .
[27] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[28] D.,et al. Regression Models and Life-Tables , 2022 .